Society for Neuro-Oncology (SNO) Conference
November 21-24, 2024 | Houston, TX
Chimerix Sponsored
Response by RANO2.0 criteria in ONC201 (dordaviprone)-treated patients with recurrent H3 K27M-mutant diffuse midline glioma
Abstract Number: CTNI-54
Date and Time: November 22, 2024 from 7:30 p.m. – 9:30 p.m. CT
Presenter: Timothy Cloughesy
Allosteric mitochondrial ClpP agonist ONC206 alters stress response, metabolic and epigenetic profiles to elicit anti-cancer efficacy in high-grade gliomas
Abstract Number: EXTH-37
Date and Time: November 22, 2024 from 7:30 p.m. – 9:30 p.m. CT
Presenter: Varun V. Prabhu
Safety of ONC201 treatment in patients with previously treated H3 K27M-mutant glioma: results from ONC028, an ongoing compassionate use program
Abstract Number: NCOG-07
Date and Time: November 23, 2024 from 5:00 p.m. – 5:05 p.m. CT
Presenter: Akanksha Sharma